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Summary
Background—Human papillomavirus (HPV) vaccination programmes were first implemented in 
several countries worldwide in 2007. We did a systematic review and meta-analysis to assess the 
population-level consequences and herd effects after female HPV vaccination programmes, to 
verify whether or not the high efficacy reported in randomised controlled clinical trials are 
materialising in real-world situations.
Methods—We searched the Medline and Embase databases (between Jan 1, 2007 and Feb 28, 
2014) and conference abstracts for time-trend studies that analysed changes, between the pre-
vaccination and post-vaccination periods, in the incidence or prevalence of at least one HPV-
related endpoint: HPV infection, anogenital warts, and high-grade cervical lesions. We used 
random-effects models to derive pooled relative risk (RR) estimates. We stratified all analyses by 
age and sex. We did subgroup analyses by comparing studies according to vaccine type, 
vaccination coverage, and years since implementation of the vaccination programme. We assessed 
heterogeneity across studies using I2 and χ2 statistics and we did trends analysis to examine the 
dose–response association between HPV vaccination coverage and each study effect measure.
Findings—We identified 20 eligible studies, which were all undertaken in nine high-income 
countries and represent more than 140 million person-years of follow-up. In countries with female 
vaccination coverage of at least 50%, HPV type 16 and 18 infections decreased significantly 
between the pre-vaccination and post-vaccination periods by 68% (RR 0·32, 95% CI 0·19–0·52) 
and anogenital warts decreased significantly by 61% (0·39, 0·22–0·71) in girls 13–19 years of age. 
Significant reductions were also recorded in HPV types 31, 33, and 45 in this age group of girls 
(RR 0·72, 95% CI 0·54–0·96), which suggests cross-protection. Additionally, significant 
reductions in anogenital warts were also reported in boys younger than 20 years of age (0·66 [95% 
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CI 0·47–0·91]) and in women 20–39 years of age (0·68 [95% CI 0·51–0·89]), which suggests herd 
effects. In countries with female vaccination coverage lower than 50%, significant reductions in 
HPV types 16 and 18 infection (RR 0·50, 95% CI 0·34–0·74]) and in anogenital warts (0·86 [95% 
CI 0·79–0·94]) occurred in girls younger than 20 years of age, with no indication of cross-
protection or herd effects.
Interpretation—Our results are promising for the long-term population-level effects of HPV 
vaccination programmes. However, continued monitoring is essential to identify any signals of 
potential waning efficacy or type-replacement.
Funding—The Canadian Institutes of Health Research.
Introduction
Since 2007, 52 out of 195 countries worldwide have implemented human papillomavirus 
(HPV) vaccination programmes, including 41% of high-income countries and 15% of low-
income and middle-income countries.1–4 The population-level effect of HPV vaccination 
programmes is expected to vary substantially between these countries, depending on the 
vaccine used, implementation strategies, and vaccination coverage achieved. Two HPV 
vaccines are currently available worldwide: the bivalent vaccine, which targets HPV types 
16 and 18 (which are associated with 70–80% of cervical cancers globally5), and the 
quadrivalent vaccine, which also targets HPV types 6 and 11 (associated with 85–95% of 
cases of anogenital warts6). Most high-income countries are using the quadrivalent vaccine, 
whereas a mixed picture exists for low-income and middle-income countries.2,7 Although all 
HPV vaccination programmes target pre-adolescent girls (and might also include catch-up 
programmes for older girls and women), a few countries, such as the USA and Australia, 
have recently begun to include boys.8,9 Finally, in high-income countries, vaccination 
coverage in the younger cohorts of girls ranges from nearly 90% to less than 50%, mostly 
depending on whether the countries have school-based or non-school-based vaccination 
programmes.10
Large international randomised controlled clinical trials have shown both HPV vaccines to 
be safe and well tolerated, highly efficacious against vaccine-type persistent HPV infection 
and precancerous cervical lesions in women (vaccine efficacy 93–100%),11,12 and to provide 
some degree of cross-protection against three non-vaccine types (HPV types 31, 33, and 
45),12–14 which are associated with 10–15% of cervical cancers worldwide.15 Existing 
evidence from clinical trials also suggests that cross-protective vaccine efficacy estimates 
against infections and lesions associated with HPV types 31, 33, and 45 are higher for the 
bivalent vaccine than for the quadrivalent vaccine.16 Following clinical trials, mathematical 
models have been used to predict the long-term population-level effectiveness and cost-
effectiveness of vaccination programmes delivered in different settings. Modelling studies 
have consistently predicted that the overall burden of HPV-related diseases in women will 
decrease substantially in the next few decades through vaccination, and that vaccination of 
girls against HPV is highly cost effective in most countries.17–19 Despite consistency in 
model predictions of the direct effects of HPV vaccination in vaccinated girls, uncertainty 
remains about the potential population-level effects of cross-protection and herd protection 
(eg, the indirect consequences of vaccinating girls on HPV in unvaccinated boys, men, and 
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adult women), and the vaccination coverage necessary to achieve substantial herd 
effects.20–24 This information is crucial to help guide vaccine choices and inform decisions 
about vaccination of boys and men.
Now that more than 7 years have elapsed since the implementation of the first HPV 
vaccination programmes in 2007 (appendix pp 2–4), it is timely to verify whether or not the 
promising results from clinical trials and model projections are materialising at the 
population level. An increasing number of post-vaccination surveillance studies have 
recently been published using several intermediate endpoints (eg, HPV infection, anogenital 
warts, and precancerous cervical lesions). The aim of this systematic review and meta-
analysis is to summarise existing evidence about the population-level effect of HPV 
vaccination, as measured in time-trend studies in girls and young women targeted for 
vaccination, and in boys, men, and older women. We focused on three HPV-related 
endpoints: HPV infection, anogenital warts, and high-grade cervical lesions.
Methods
Search strategy and selection criteria
We systematically reviewed the global literature and report it in accordance with the 
PRISMA guidelines.25 Studies were eligible for inclusion if they fulfilled the following 
criteria: they provided data about at least one endpoint of HPV infection, anogenital warts, 
histopathologically confirmed high-grade cervical lesions (cervical intraepithelial neoplasia 
[CIN] 2 or worse); if they assessed the population-level effect by comparing the frequency 
(prevalence or incidence) of the endpoint between the pre-vaccination and post-vaccination 
periods (ie, time-trend studies); and if data from the pre-vaccination and post-vaccination 
periods were collected from the same population sources with use of the same recruitment 
methods.
We excluded studies with the following characteristics because they did not measure 
population-level effect: if HPV vaccination was administered as part of an individual-based 
randomised trial, or HPV vaccination effect was assessed by comparing the frequency of the 
endpoint between vaccinated and unvaccinated people during the post-vaccination period.
Our search strategy had three stages. First, we searched the Medline and Embase databases 
between Jan 1, 2007, and Feb 28, 2014, with a combination of the following Medical 
Subject Heading (MeSH) terms, title, or abstract words, with no restriction on the language 
of publication: (“papillomavirus vaccine”, “papillomavirus vaccination”, “HPV vaccine”, or 
“HPV vaccination”) and (“program evaluation”, “population surveillance”, “sentinel 
surveillance”, “incidence”, or “prevalence”), and (“papillomavirus infection”, “condylomata 
acuminata”, “anogenital warts”, “cervical intraepithelial neoplasia”, “cervical dysplasia”, 
“uterine cervical neoplasm”, or “HPV related diseases”). We identified eligible studies by 
reviewing titles and abstracts, and we also searched the reference lists of eligible articles. 
Second, we reviewed the abstracts of recent major conferences on HPV (the European 
Research Organisation on Genital Infection and Neoplasia [EUROGIN] Congress 2013 and 
the International Papillomavirus Conference 2012) to identify additional unpublished 
studies. Third, MD and MB contacted the authors of conference abstracts to obtain 
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unpublished data. MD and EB independently assessed the eligibility of all studies. 
Additionally, DM independently assessed the eligibility of studies of HPV infection. If more 
than one publication from the same data source and research team was available, we kept the 
publication that presented the most recent data.
Data extraction and quality assessment
Our primary outcomes were the relative risks (RR) comparing the pre-vaccination and post-
vaccination periods for: the prevalence of HPV infection for four HPV type subgroups 
(high-oncogenic risk vaccine types [HPV16 and HPV18], three types with the greatest 
evidence of cross-protective efficacy [HPV31, HPV33, and HPV45],16 the five potentially 
cross-protective types [HPV31, HPV33, HPV45, HPV52, and HPV58],16 and all high-
oncogenic risk non-vaccine types [all high-risk HPV types except for HPV16 and HPV18]); 
the frequency (prevalence or incidence) of anogenital wart diagnosis; and the frequency 
(prevalence or incidence) of high-grade cervical lesions. Two authors (MD and EB) 
independently extracted the study characteristics and outcomes using a standardised form. 
MD and MB contacted authors to request supplementary extractions to standardise data 
stratifications between studies for comparison and pooling (eg, same age and HPV type 
groupings). We also collected information about the vaccination programme characteristics 
and vaccination coverage of the country or region of each study (appendix pp 2–4). For the 
HPV prevalence studies, we collected age-specific vaccination coverage directly from each 
study, since vaccination status was available for all study participants. Finally, the authors of 
each article validated the data from their study.
Before contacting the study investigators, MD, AM, PLM, and MB assessed whether or not 
the studies had sufficient methodological quality to be included in the meta-analysis. The 
quality of the studies (potential for bias and confounding, and external validity) was assessed 
independently from the investigators of the original studies. Potential for bias and 
confounding within studies were assessed by review of the participant selection or 
recruitment procedures, endpoint definitions, algorithms used to identify cases, and potential 
confounders considered in the statistical analyses (appendix pp 5–9).
Data analysis
Because mostly girls (<20 years of age) were vaccinated in the study populations, we 
decided a priori to stratify all our analyses by sex and age. Furthermore, because only the 
quadrivalent vaccine includes HPV types 6 and 11 (which are responsible for roughly 90% 
of cases of anogenital warts6), we decided a priori to stratify our analyses for anogenital 
warts by the type of vaccine.
To ensure comparability of the study results included in the meta-analysis, we first defined 
pre-vaccination and post-vaccination periods for all studies (appendix pp 10–11). Second, 
for comparability, we used prevalence or incidence rate ratios as the measure of effect for all 
HPV-related endpoints. For HPV infection, most studies presented RR (crude and/or 
adjusted prevalence ratios) and 95% CIs. When available, we included adjusted RR in the 
meta-analysis. When only crude HPV prevalence over time was available, we calculated 
prevalence ratios by dividing the post-vaccination and pre-vaccination prevalence and 
Drolet et al. Page 5
Lancet Infect Dis. Author manuscript; available in PMC 2016 December 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
estimated the 95% CI (CI approximation for prevalence ratios26). For anogenital warts and 
precancerous lesions, all studies presented annual frequency (prevalence or incidence) over 
time. We estimated pre-vaccination frequency by aggregating the data for up to 3 years 
before vaccination, and calculated RR by dividing each post-vaccination year by the pre-
vaccination estimate.
We derived summary estimates of the effect of HPV vaccination for each endpoint by using 
random-effects models on the log scale.27,28 We did a subgroup analysis to identify potential 
sources of heterogeneity by comparing the summary estimates obtained from subsets of 
studies or groups within studies grouped by: vaccine type (bivalent or quadrivalent), 
vaccination coverage (low <50% or high ≥50%—we used study-specific coverage estimates 
for HPV infection, and country/region-level coverage for the other outcomes), age (<20, 20–
24, 25–29, or 30–39 years), years since the vaccination programme was implemented (1, 2, 
3, or 4 years), source of study data (population based, health provider/insurance based, or 
clinic based), and by whether or not the impact measure was adjusted (yes or no). We 
examined heterogeneity across studies using I2 and χ2 statistics.28 I2 values less than 50% 
represent low heterogeneity, between 50–75% substantial heterogeneity, and more than 75% 
high heterogeneity.29 The p value associated with the χ2 statistic represents the statistical 
significance of heterogeneity. Finally, we analysed the dose–response association between 
HPV vaccination coverage (independent variable) and the log-RR of each study (dependent 
variable) by fitting a linear regression, weighted by the inverse variances of the log-RR.30 
We used Review Manager 5.2 and SAS 9.4 for all analyses.
Role of the funding source
The funders had no role in the study design, data collection, analysis and interpretation, or 
writing of the report. MB had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
In our searches we identified 661 articles and 29 conference abstracts, of which 20 records 
met the inclusion criteria (seven on HPV infection,31–37 11 on anogenital warts,38–48 and 
two on high-grade cervical lesions;49,50 figure 1, table). The studies were done in nine high-
income countries (the USA, Australia, England, Scotland, New Zealand, Sweden, Denmark, 
Canada, and Germany) and assessed the population-level consequences of vaccination in 16 
600 women for HPV infection, more than 125 million person-years of follow-up for 
anogenital warts, and 15 million female-years of follow-up for high-grade cervical lesions 
(table). The vaccine used, vaccination strategy, delivery, and vaccination coverage varied 
substantially (table and appendix pp 2–4). All studies had sufficient methodological quality 
to be included in the meta-analysis (appendix pp 5–9). However, because two studies 
analysed the entire Danish population during identical time periods,43,48 we only included 
Baandrup and colleagues’ study43 in our main analysis (the choice of study had no effect on 
our results; appendix pp 12–14).
In girls 13–19 years of age, the overall prevalence of HPV types 16 and 18 decreased 
significantly by 64% in the post-vaccination period (RR 0·36 [95% CI 0·25–0·53]) compared 
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with the pre-vaccination period (figure 2A), with a significant dose–response association 
with vaccination coverage (p=0·005). The overall prevalence of HPV types 31, 33, and 45 
also decreased significantly post-vaccination by 28% (RR 0·72 [95% CI 0·54–0·96]), but the 
reductions were not associated with vaccination coverage. The overall prevalence of HPV 
types 31, 33, 45, 52, and 58, and non-vaccine high-risk types (ie, all high-risk HPV types 
except HPV16 and HPV18) did not change significantly between the pre-vaccination and 
post-vaccination periods (figure 2A).
In women 20–24 years of age, the overall prevalence of HPV types 16 and 18 decreased by 
31% (RR 0·69 [95% CI 0·47–1·01]) in the post-vaccination period (figure 2B). Although the 
overall reduction in HPV16 and HPV18 infection was not significant, it showed a dose–
response association with vaccination coverage (p=0·01). No significant decreases in 
prevalence or dose–response associations with vaccination coverage were recorded for HPV 
types 31, 33, and 45, or for HPV types 31, 33, 45, 52, and 58. Finally, a small—but non-
significant—increase in non-vaccine high-risk HPV types occurred (RR 1·09, 95% CI 0·98–
1·22), which was negatively associated with increasing vaccination coverage (p=0·03).
In addition to vaccination coverage, the use of adjusted or crude RRs emerged as a 
substantial source of heterogeneity between studies (I2 ranged between 50% and 75% for 
many endpoints; figure 3). Notably, the point estimates of adjusted RRs were lower than 
were the crude RRs for HPV subgroups with substantial post-vaccination reductions (ie, 
HPV types 16 and 18 in 20–24-year-old women; figure 3B, and HPV types 16 and 18 and 
types 31, 33, and 45 in 13–19 year-old girls; figure 3A), but were higher than the crude RRs 
for the other endpoints (figure 3).
In girls aged 15–19 years in countries using the quadrivalent vaccine, anogenital warts 
decreased significantly by 31% (RR 0·69 [95% CI 0·60–0·79]) in the post-vaccination 
period. A notable dose–response association was recorded between anogenital wart 
reduction and increase in population-level female vaccination coverage (p=0·0007; figure 
4A). In the same group, anogenital warts were reduced more substantially (by 61%) in 
studies with high vaccination coverage than in those with low vaccination coverage (14% 
reduction; figure 5A). In addition to vaccination coverage, years since the start of 
vaccination emerged as a significant source of heterogeneity (I2=68%, p=0·02; figure 5A).
In countries that used the quadrivalent vaccine, nonsignificant decreases in anogenital warts 
were recorded post-vaccination in women 20–39 years of age (11%, RR 0·89 [95% CI 0·79–
1·02]) and in boys 15–19 years of age (5%, 0·95 [0·84–1·08]; figure 4B, 4C). Again, these 
reductions showed a significant dose–response association with increased population-level 
female vaccination coverage (p=0·05 for older women and p=0·005 for young men). 
Subgroup analyses showed that female vaccination coverage was a main source of 
heterogeneity (figure 5B, 5C). In countries with high female vaccination coverage, 
anogenital warts were reduced significantly by 32% in women aged 20–39 years (RR 0·68 
[95% CI 0·51–0·89]) and by 34% in boys aged 15–19 years (0·66 [0·47–0·91]). No changes 
in anogenital warts were recorded in men aged 20–39 years in countries using the 
quadrivalent vaccine (figure 4D).
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The only study that assessed population-level changes in anogenital warts following 
vaccination with the bivalent vaccine44 reported a small but significant decrease in these 
warts in girls aged 15–19 years (figure 4A). Conversely, a small but significant increase in 
anogenital warts was recorded in boys aged 15–19 years (figure 4C), and no significant 
effect was noted in older people of either sex (figure 4B, 4D).
Figure 6 shows the changes over time in anogenital warts in studies of the quadrivalent 
vaccine, with the main sources of heterogeneity taken into consideration. Figure 6A clearly 
shows a rapid and significant decrease in anogenital warts over time in girls and women 
younger than 30 years of age in studies with high vaccination coverage. However, in studies 
with low vaccination coverage (figure 6B), the decline was recorded only in girls younger 
than 20 years of age, and became significant only in the third year after vaccination 
implementation. A rapid and significant decline in anogenital warts over time also occurred 
in boys and men younger than 30 years of age in studies with high female vaccination 
coverage (figure 6C). However, in studies with low female vaccination coverage, there was a 
general pattern of anogenital warts increasing over time, particularly in older men (figure 
6D).
A significant decrease in high-grade precancerous cervical lesions was recorded in the only 
study49 that reported these data for girls aged 15–19 years (RR 0·69, 95% CI 0·66–0·73), but 
no significant change was recorded in the two studies reporting data in women aged 20 years 
and older (appendix p 15).
Discussion
This systematic review and meta-analysis, representing more than 140 million person-years 
of follow-up data from nine high-income countries, reports significant population-level 
decreases in HPV-related outcomes up to 4 years after the implementation of HPV 
vaccination programmes. In countries with high vaccination coverage, HPV16 and HPV18 
infection, and anogenital warts decreased by more than 60% in girls younger than 20 years 
of age, starting after the first year of the vaccination programmes. Furthermore, in these 
countries, our results suggest evidence of vaccine cross-protection and herd effects, with 
significant reductions in HPV31, HPV33, and HPV45 infection in girls younger than 20 
years of age, and in anogenital warts in men and older women. In countries with low 
vaccination coverage, significant reductions were recorded for HPV16 and HPV18 infection 
and anogenital warts in girls younger than 20 years of age, but no significant reductions 
were noted for HPV31, HPV33, and HPV45 in this group, or HPV-related outcomes in boys, 
men, and older women (ie, no indication of cross-protection or herd effects). Our findings 
provide strong evidence that HPV vaccination is highly effective and can provide cross-
protection outside trial settings, and reinforce the need for early vaccination and high 
vaccination coverage to maximise population-level effectiveness and herd effects.
Although this meta-analysis is based on time-trend ecological studies, and therefore 
causality cannot be concluded, several factors strongly suggest that the reported reductions 
in population-level HPV-related outcomes can be attributed to HPV vaccination. These 
factors are: the magnitude of the effect; the dose–response association between vaccination 
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coverage and effect; and consistency, both between the studies included in the review 
(despite the different methods and settings) and with results from clinical trials and 
mathematical modelling. First, reductions in HPV types 16 and 18, anogenital warts, and 
high-grade cervical lesions were large and statistically significant in the target age groups for 
vaccination (girls <20 years of age). Second, we found a statistically significant positive 
association between increases in vaccination coverage and reduction in HPV types 16 and 18 
infection in girls younger than 20 years of age and anogenital warts in both women and men. 
Furthermore, reductions in anogenital warts increased over time since vaccination (as the 
number of vaccinated cohorts increased), especially in youngest age groups with highest 
vaccination coverage. Third, the results showed consistency between countries with similar 
levels of vaccination coverage. Furthermore, in the studies in which the vaccine status was 
available, vaccinated women had significantly lower HPV-related outcomes than did 
unvaccinated women in the post-vaccination era.32–34,37,42,53–56 Our results are also 
consistent with data from clinical trials that showed a high vaccine-type efficacy,11,12 and 
suggested some degree of cross-protection against HPV types 31, 33, and 45, but not against 
types 52 or 58.16 However, the higher bivalent cross-protective efficacy reported in a recent 
meta-analysis of clinical trial data16 was not shown in our population-level meta-analysis. 
Finally, the large herd effects reported with high vaccination coverage are consistent with 
predictions from dynamic models.20–24
The studies included in the meta-analysis possess the strengths and weaknesses inherent in 
ecological studies. They provide a wealth of timely information about the effects of HPV 
vaccination using large study populations, but are especially vulnerable to information bias 
and confounding (appendix pp 5–9). However, the three most important potential sources of 
bias and confounding in these studies are likely to underestimate the effect of vaccination. 
First, because of increased awareness of anogenital warts from licensing of the HPV 
vaccines and the launch of the vaccination programmes, potential exists for confounding 
related to possible increases in health-seeking behaviours and information bias from 
increased diagnosis of anogenital warts over time.
Second, most studies had insufficient or no information to adequately control for sexual 
activity, which might have been increasing over time.43,57,58 These limitations might explain 
the slight increase in the prevalence of non-vaccine high-risk HPV types and anogenital wart 
consultations in the post-vaccination period within groups with low or no vaccination 
coverage (eg, women older than 20 years, and men).
Third, information bias might be present as a consequence of masking by HPV type 16 and 
18, especially in the pre-vaccine period.59 That is, by preventing HPV16 and HPV18 
infection, vaccination could remove the potential masking effect of these types, producing 
increased detection of non-vaccine types. Conversely, the main potential source of 
overestimation of vaccination effects is present in clinic-based studies that measure the 
proportion of consultations attributable to anogenital warts in sexual health clinics (appendix 
pp 7–8).38,42 Indeed, changes in the clientele of the clinics between the pre-vaccination and 
post-vaccination periods could overestimate the vaccination effect on anogenital warts if 
consultations due to other causes (eg, chlamydia consultations42) became more frequent. 
Clinic-based studies represent two-thirds of the studies assessing the population-level effect 
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of vaccination on anogenital warts in countries with high vaccination coverage, and could 
partly explain slight reductions in anogenital warts in adult men.
Fourth, the external validity of the studies was generally good (appendix pp 5–9). However, 
because most studies were undertaken on individuals consulting the health system, the 
results for the effect of HPV vaccination might not be completely generalisable to groups 
with lower levels of health-seeking behaviour, especially in countries in which the HPV 
vaccine is delivered in health-care clinics. Finally, in view of the indirect nature of our 
inferences, our analysis might not have had adequate sensitivity to detect small post-
vaccination effects (eg, type-replacement, or herd effects and cross-protection when 
vaccination coverage is low).
Our results should be interpreted cautiously because they represent only the short-term 
population-level effects of HPV vaccination programmes. First, the cohorts of vaccinated 
girls have not yet reached the ages with highest incidence rates of HPV infection, anogenital 
warts, and cervical lesions (ie, between 20 and 35 years of age). Therefore, the direct and 
herd effects are expected to continue to increase over time as overall population-level 
vaccination coverage increases.
Second, the existing evidence is insufficient to draw conclusions about the existence of net 
type-replacement (eg, no significant increase in the prevalence of high-risk non-vaccine 
HPV types in groups with the highest vaccination coverage), which could be because no 
type-replacement is occurring, or partly a consequence of the short follow-up time or 
dilution of type-specific changes by grouping HPV types.
Third, the time horizon was too short to examine waning of vaccine efficacy. However, 
randomised controlled trials have shown no signs of waning vaccine efficacy after 9·5 years 
of follow-up.60
Fourth, in view of the long lag time between infection and cancer, no direct evidence of the 
effect of vaccination on HPV-related cancers is currently available. However, since HPV 
infection is the cause—and high-grade precancerous cervical lesions the precursors—of 
cervical cancer, these intermediate outcomes have been judged acceptable proxies for 
efficacy against cervical cancer by regulatory bodies worldwide.61–64 Nevertheless, one 
should be careful in using reductions in precancerous cervical lesions from screening 
databases as proxies for cervical cancer because they might represent changes in screening 
recommendations and participation, and they are not HPV type-specific. Additionally, 
surveillance studies based on cervical screening registries could overestimate the population-
level effect of HPV vaccination, if vaccine uptake is higher in women who undergo 
screening.65–68
Finally, as previously shown, trends in HPV types 6 or 11-related disease (eg, anogenital 
warts) are a poor proxy of change in HPV types 16 and 18 and related diseases (eg, cervical 
cancer).69 This is because HPV6 and HPV11 will be easier to eliminate and control through 
vaccination than HPV16 and HPV18 because of their shorter durations of infectiousness and 
lower transmissibility.
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Our overall findings are likely generalisable to high-income countries, since most of the 
heterogeneity between countries disappeared once results were stratified by vaccination 
coverage and age, and given similarities in sexual behaviour,58 HPV type distribution,70,71 
age profile of HPV prevalence,72 and cervical cancer incidence between high income 
countries.73 However, precise estimates of population-level effect will vary between 
countries according to their programmatic specificities, such as the characteristics of catch-
up campaigns.
Our results should be extrapolated to low-income and middle-income countries with caution 
because all studies in the meta-analysis were from high-income countries and substantial 
differences exist between these countries and low-income and middle-income countries in 
sexual behaviour,58 HPV epidemiology,72,73 and potential cofactors of HPV infection and 
disease, such as high HIV prevalence.74 However, no evidence exists to suggest that vaccine 
efficacy would be lower in low-income and middle-income countries, especially because the 
vaccine has been shown safe and immunogenic in women with HIV infection.75 On the 
other hand, herd effects could differ in low-income and middle-income countries with very 
different population-level sexual behaviour (eg, increased mixing between older men and 
younger women, and more concurrency in partnerships). Even in the unlikely scenario that 
there would be no herd effects in such countries, a recent global modelling study (PRIME)19 
has shown that HPV vaccination would be highly cost effective, in view of the very high 
cervical cancer incidence and mortality in these countries,
This first meta-analysis of the population-level effect of HPV vaccination programmes 
shows compelling evidence of a strong and statistically significant dose–response 
association between HPV vaccination coverage and reductions in HPV16 and HPV18 
infection and anogenital warts in cohorts of girls and women targeted for vaccination. 
Additionally, our study provides the first evidence of a dose–response association between 
female vaccination coverage and reduction of anogenital warts in older women and men.
Our results have important policy implications. The sharpest declines in HPV-related 
outcomes in both male and female participants were recorded in countries with school-based 
vaccine delivery (eg, the UK, Australia, and New Zealand), which suggests that this strategy 
helps faster rollout and higher vaccination coverage than non-school-based vaccine 
programmes. Our study also shows population-level data supporting clinical trial evidence of 
HPV vaccine cross-protection against HPV types 31, 33, and 45, although no dose–response 
with vaccination coverage was recorded.
In conclusion, the results of this study are very promising for the long-term population-level 
effect of HPV vaccination programmes on cervical cancer and other HPV-related diseases. 
However, we must continue to monitor and evaluate HPV vaccination programmes to 
confirm these results, and we need to remain vigilant for evidence of potential waning 
efficacy, type-replacement, or lower vaccination coverage in groups at greater risk of HPV-
related cancers.
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Figure 1. 
Study selection
EUROGIN=EUropean Research Organisation on Genital Infection and Neoplasia. 
IPV=International Papillomavirus Conference. HPV=human papillomavirus.
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Figure 2. 
Changes in the prevalence of HPV infections between the prevaccination and 
postvaccination periods in (A) girls aged 13–19 years and (B) women aged 20–24 years, 
ranked by age-specific vaccination coverage (≥1 dose) reported in studies
RR=relative risk. HPV=human papillomavirus. NA=not available. p values for trends were 
obtained by fitting a linear regression between the log RR and the age-specific coverage of 
each study, weighted by the inverse variances of the log RR. The minimum age of 
participants varied between studies (see table 1). *Age-specific proportion of female 
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participants, included in the analysis of each study, who received at least one dose of the 
HPV vaccine. †Data not available for girls aged 13–19 years in Kavanagh et al, and for 
women aged 20–24 years in Cummings et al. ‡Data not provided because they were judged 
potentially unreliable according to National Health and Nutrition Examination Survey 
analytic guidelines:52 prevalence estimates had a relative standard error of >30% and the 
sample size was below that recommended for analyses of complex survey data, by design 
effect and specified proportion. The only other data excluded were for HPV types 31/33/45 
from NATSAL: unweighted prevaccination prevalence: 3/85; unweighted postvaccination 
prevalence: 16/215; weighted prevalence ratio 3·50 (95% CI 0·97–12·67)
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Figure 3. 
Subgroup analyses of the changes in the prevalence of HPV infections between the 
prevaccination and postvaccination periods in (A) girls aged 13–19 years and (B) women 
aged 20–24 years
RR=relative risk. HPV=human papillomavirus. NA=not available.
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Figure 4. 
Changes in anogenital wart diagnosis between the pre-vaccination and post-vaccination 
periods in (A) girls aged 15–19 years, (B) women aged 20–39 years, (C) boys aged 15–19 
years, and (D) men aged 20–39 years, ranked by the national or setting-specific female 
vaccination coverage
RR=relative risk. p values for trends were obtained by fitting a linear regression between the 
log RR and the rank of vaccination coverage of each study, weighted by the inverse 
variances of the log RR. *Before vaccination: cumulative number of cases and person-years 
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up to 3 years pre-vaccination, including the year of the introduction of the human 
papillomavirus (HPV) vaccine. †After vaccination: cumulative number of cases and person-
years 1–4 years after the introduction of vaccination, depending on data available in each 
study. ‡Years of post-vaccination follow-up: number of years after the introduction of HPV 
vaccination considered in the meta-analysis (see appendix pp 10–11 for more details). 
§Studies were ranked qualitatively by the national or setting-specific vaccination coverage, 
for which we considered the number of cohorts vaccinated and vaccination coverage 
achieved in each cohort. However, we could not estimate the overall vaccination coverage 
for each study (see appendix pp 2–4 for details about the programme description, number of 
cohorts vaccinated, and three-dose vaccination coverage for each study).
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Figure 5. 
Subgroup analyses of the changes in anogenital wart diagnosis between the pre-vaccination 
and post-vaccination periods in (A) girls aged 15–19 years, (B) women aged 20–39 years, 
(C) boys aged 15–19 years, and (D) men aged 20–39 years
Data are for years with female-only vaccination programmes. RR=relative risk.
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Figure 6. 
Changes in anogenital wart diagnosis during the first 4 years after the introduction of human 
papillomavirus vaccination with the quadrivalent vaccine
Results are stratified by age and female vaccination coverage: (A) Girls and women, with 
high female vaccination coverage (≥50%); (B) girls and women, with low female 
vaccination coverage (<50%); (C) boys and men, with high female vaccination coverage 
(≥50%); (D) boys and men, with low female vaccination coverage (<50%). For high 
coverage, the results from the following studies were combined depending on the years of 
follow-up available: years 1 and 2: Oliphant and Perkins (2011),38 Baandrup et al (2013),43 
and Ali et al (2013);42 years 3 and 4: Ali et al (2013).42 For low coverage, the results from 
the following studies were combined depending on the years of follow-up available: year 1: 
Leval et al (2013),41 Kliewer et al (2012),40 Flagg et al (2013),45 Nsouli-Maktabi et al 
(2013),47 and Mikolajczyk et al (2013);46 years 2, 3, and 4: Leval et al (2013),41 Flagg et al 
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(2013),45 Nsouli-Maktabi et al (2013),47 and Bauer et al (2013).39 See appendix pp 2–4 for 
information about vaccination coverage in each study.
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in
al
 st
ud
ie
s. 
Fo
r 
st
ud
ie
s o
f a
no
ge
ni
ta
l w
ar
ts
 a
nd
 c
er
vi
ca
l l
es
io
ns
, t
he
 p
re
-v
ac
ci
na
tio
n 
sa
m
pl
e 
siz
e 
co
rre
sp
on
ds
 to
 th
e 
cu
m
ul
at
iv
e 
n
u
m
be
r o
f p
er
so
n-
ye
ar
s u
p 
to
 3
 y
ea
rs
 p
re
-v
ac
ci
na
tio
n,
 in
cl
ud
in
g 
th
e 
ye
ar
 o
f t
he
 in
tro
du
ct
io
n 
of
 
H
PV
 v
ac
ci
na
tio
n.
 T
he
 p
os
t-v
ac
ci
na
tio
n 
sa
m
pl
e 
siz
e 
co
rre
sp
on
ds
 to
 th
e 
cu
m
ul
at
iv
e 
n
u
m
be
r o
f p
er
so
n-
ye
ar
s f
ro
m
 1
–4
 y
ea
rs
 a
fte
r t
he
 in
tro
du
ct
io
n 
of
 v
ac
ci
na
tio
n,
 d
ep
en
di
ng
 o
n 
th
e 
da
ta
 av
ai
la
bl
e 
in
 e
ac
h 
stu
dy
.
§ F
o
r 
H
PV
 in
fe
ct
io
n,
 th
e 
in
v
es
tig
at
or
s 
re
ca
lc
ul
at
ed
 th
e 
RR
 o
f p
re
v
al
en
ce
 u
sin
g 
th
e 
or
ig
in
al
 d
at
a 
fro
m
 th
ei
r s
pe
ci
fic
 st
ud
ie
s. 
Fo
r 
an
o
ge
ni
ta
l w
ar
ts
 a
nd
 p
re
ca
nc
er
ou
s l
es
io
ns
, w
e 
es
tim
at
ed
 p
re
-v
ac
ci
na
tio
n 
fre
qu
en
cy
 b
y 
ag
gr
eg
at
in
g 
th
e 
da
ta
 fo
r u
p 
to
 th
re
e 
ye
ar
s b
ef
or
e 
va
cc
in
at
io
n,
 a
nd
 c
al
cu
la
te
d 
RR
 b
y 
di
v
id
in
g 
ea
ch
 p
os
t-v
ac
ci
na
tio
n 
ye
ar
 b
y 
th
e 
pr
e-
va
cc
in
at
io
n 
es
tim
at
e.
¶ 1
3 
hi
gh
-ri
sk
 H
PV
 ty
pe
s w
er
e 
pr
es
en
te
d 
in
 th
e 
or
ig
in
al
 p
ub
lic
at
io
ns
, w
he
re
as
 th
e 
18
 h
ig
h-
ris
k 
H
PV
 ty
pe
s a
v
ai
la
bl
e 
w
er
e 
us
ed
 fo
r t
he
 p
ur
po
se
s o
f t
hi
s m
et
a-
an
al
ys
is.
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∥ D
at
a 
fro
m
 th
is 
stu
dy
 a
re
 re
str
ic
te
d 
to
 th
e 
Vi
ct
or
ia
n 
re
gi
str
y 
da
ta
. S
up
pl
em
en
ta
ry
 d
at
a 
fro
m
 th
e 
A
us
tra
lia
n 
In
sti
tu
te
 o
f H
ea
lth
 a
nd
 W
el
fa
re
 2
01
3 
re
po
rt5
1  
w
er
e 
pr
ov
id
ed
 b
y 
Br
ot
he
rto
n 
(JM
L 
Br
oth
ert
on
, 
N
at
io
na
l H
PV
 V
ac
ci
na
tio
n 
Pr
og
ra
m
 R
eg
ist
er
,
 
Vi
ct
or
ia
n 
Cy
to
lo
gy
 S
er
vi
ce
, E
as
t M
el
bo
ur
ne
, M
el
bo
ur
ne
, V
IC
, A
us
tra
lia
, p
er
so
na
l c
om
m
un
ic
at
io
n).
 Si
nc
e t
he
 re
po
rt 
co
v
er
s 
al
l r
eg
io
ns
 o
f A
us
tra
lia
, w
e 
us
ed
 it
 
as
 o
u
r 
m
ai
n 
da
ta
 so
ur
ce
 fo
r t
he
 re
v
ie
w
.
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